ACTA1 and chronic myelogenous leukemia, BCR-ABL1 positive: In the analysis of protein expression of markers of vascular remodeling, we noted an increase in the expression of α-SMA and CD31 following treatment of VSMCs cells with CML-BSA; this effect was inhibited by treatments with Mdivi-1, stattic, and siRAGE (Figure 5(b)).